News & Updates

Show Multimedia Only

Biosimilar DMARDs cost-effective vs leflunomide in RA patients after MTX failure

07 Aug 2024 by

An economic evaluation study by the University of Hong Kong (HKU) found treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) to be cost-effective compared with leflunomide in patients with rheumatoid arthritis (RA) who failed initial treatment with methotrexate (MTX).

Biosimilar DMARDs cost-effective vs leflunomide in RA patients after MTX failure

07 Aug 2024

Giant cell arteritis diagnosis raises healthcare costs

05 Aug 2024

People diagnosed with giant cell arteritis (GCA) tend to have higher healthcare expenses during all three phases of care, according to a study conducted in Ontario, Canada.

Giant cell arteritis diagnosis raises healthcare costs

05 Aug 2024

Tofacitinib for JIA safe, effective up to 4 years

02 Aug 2024

In the treatment of patients with juvenile idiopathic arthritis (JIA), tofacitinib appears to maintain its efficacy for up to 48 months, with the safety findings consistent with the known safety profile of the drug, according to the results of a long-term extension (LTE) study.

Tofacitinib for JIA safe, effective up to 4 years

02 Aug 2024

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

01 Aug 2024 by

The JAK inhibitor upadacitinib brought sustained remission in the first 52 weeks of the phase III SELECT-GCA study of patients with new-onset or relapsing giant cell arteritis (GCA).

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

01 Aug 2024

First-line abatacept improves disease remission in RA

01 Aug 2024

The use of abatacept as a first-line biologic treatment appears to result in greater remission in rheumatoid arthritis (RA), especially if the drug is used continuously, as shown in a real-world study from Taiwan.

First-line abatacept improves disease remission in RA

01 Aug 2024

Dietary manganese helps lower uric acid levels in Chinese adults

23 Jul 2024

Eating foods high in manganese appears to confer protection against hyperuricaemia in Chinese adults, as shown in a study.

Dietary manganese helps lower uric acid levels in Chinese adults

23 Jul 2024

Bimekizumab may protect against uveitis in axial spondyloarthritis

22 Jul 2024

In the treatment of patients with axial spondyloarthritis (axSpA), the dual IL-17A/F inhibitor bimekizumab appears to lower the risk of uveitis, according to a study.

Bimekizumab may protect against uveitis in axial spondyloarthritis

22 Jul 2024

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

22 Jul 2024 by

Benralizumab offers more sustained and earlier elimination of oral GCs vs mepolizumab in patients with relapsing or refractory EGPA, suggests a post hoc analysis of the MANDARA study presented at EULAR 2024

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

22 Jul 2024

JAK inhibitors for autoimmune disease may confer protection against AMD

20 Jul 2024 by

The use of Janus kinase (JAK) inhibitors in the treatment of major autoimmune diseases appears to reduce the risk of age-related macular degeneration (AMD) for people above 40 years of age, according to a study.

JAK inhibitors for autoimmune disease may confer protection against AMD

20 Jul 2024

Nearly 9 in 10 children with juvenile PsA or ERA achieve ACR30 with ixekizumab

19 Jul 2024 by

Treatment with ixekizumab resulted in almost 90 percent of children with active juvenile psoriatic arthritis (JPsA) or enthesitis-related arthritis (ERA) achieving an ACR30* response by week 16, according to the ongoing COSPIRIT-JIA trial presented at EULAR 2024.

Nearly 9 in 10 children with juvenile PsA or ERA achieve ACR30 with ixekizumab

19 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Biosimilar DMARDs cost-effective vs leflunomide in RA patients after MTX failure

Biosimilar DMARDs cost-effective vs leflunomide in RA patients after MTX failure

Giant cell arteritis diagnosis raises healthcare costs

Giant cell arteritis diagnosis raises healthcare costs

Tofacitinib for JIA safe, effective up to 4 years

Tofacitinib for JIA safe, effective up to 4 years

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

First-line abatacept improves disease remission in RA

First-line abatacept improves disease remission in RA

Dietary manganese helps lower uric acid levels in Chinese adults

Dietary manganese helps lower uric acid levels in Chinese adults

Bimekizumab may protect against uveitis in axial spondyloarthritis

Bimekizumab may protect against uveitis in axial spondyloarthritis

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

JAK inhibitors for autoimmune disease may confer protection against AMD

JAK inhibitors for autoimmune disease may confer protection against AMD

Nearly 9 in 10 children with juvenile PsA or ERA achieve ACR30 with ixekizumab

Nearly 9 in 10 children with juvenile PsA or ERA achieve ACR30 with ixekizumab